MedTrace Logo

Measuring the Neuroimmune Response to Alcohol

NCT04251221 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

This study uses positron emission tomography imaging of the 18-kDa translocator protein to measure the brain's immune response to alcohol.

Conditions

  • Alcohol Drinking

Interventions

DRUG

Oral Alcohol Challenge

Subjects will drink an alcohol dose designed to achieve a BAL of 0.08

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Ansel T Hillmer, Ph.D. · Yale University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-06-20
Primary Completion
2021-11-20
Completion
2021-11-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04251221 on ClinicalTrials.gov